New York State Common Retirement Fund Increases Stake in Kymera Therapeutics, Inc. $KYMR

New York State Common Retirement Fund raised its position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 67.7% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 24,396 shares of the company’s stock after acquiring an additional 9,847 shares during the quarter. New York State Common Retirement Fund’s holdings in Kymera Therapeutics were worth $1,381,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of KYMR. PNC Financial Services Group Inc. lifted its position in shares of Kymera Therapeutics by 506.6% during the 2nd quarter. PNC Financial Services Group Inc. now owns 922 shares of the company’s stock worth $40,000 after purchasing an additional 770 shares during the last quarter. Osaic Holdings Inc. lifted its holdings in Kymera Therapeutics by 18,050.0% during the 2nd quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock worth $48,000 after buying an additional 1,083 shares during the last quarter. Raymond James Financial Inc. acquired a new position in shares of Kymera Therapeutics during the 2nd quarter worth about $73,000. Lazard Asset Management LLC purchased a new position in shares of Kymera Therapeutics in the 2nd quarter valued at about $116,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Kymera Therapeutics by 9.9% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,764 shares of the company’s stock valued at $156,000 after acquiring an additional 248 shares during the last quarter.

Kymera Therapeutics Stock Down 0.7%

Shares of NASDAQ:KYMR opened at $79.02 on Tuesday. Kymera Therapeutics, Inc. has a 52 week low of $19.44 and a 52 week high of $103.00. The company has a 50-day moving average price of $76.85 and a 200 day moving average price of $61.26. The company has a market cap of $5.69 billion, a P/E ratio of -22.01 and a beta of 2.21.

Insider Activity

In other Kymera Therapeutics news, CEO Nello Mainolfi sold 100,000 shares of the stock in a transaction on Monday, December 8th. The stock was sold at an average price of $89.17, for a total value of $8,917,000.00. Following the completion of the transaction, the chief executive officer owned 660,482 shares in the company, valued at approximately $58,895,179.94. This represents a 13.15% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Jeffrey W. Albers sold 5,000 shares of the firm’s stock in a transaction on Monday, December 8th. The shares were sold at an average price of $89.76, for a total value of $448,800.00. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 420,895 shares of company stock valued at $37,778,351 over the last three months. 16.01% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on KYMR. Truist Financial boosted their target price on Kymera Therapeutics from $80.00 to $116.00 and gave the stock a “buy” rating in a research note on Tuesday, December 9th. Bank of America boosted their price objective on shares of Kymera Therapeutics from $71.00 to $112.00 and gave the stock a “buy” rating in a research report on Tuesday, December 9th. Jefferies Financial Group upped their target price on shares of Kymera Therapeutics from $73.00 to $122.00 and gave the company a “buy” rating in a report on Tuesday, December 9th. Mizuho lifted their price target on shares of Kymera Therapeutics from $81.00 to $120.00 and gave the stock an “outperform” rating in a research note on Thursday, December 11th. Finally, Leerink Partners upped their price objective on shares of Kymera Therapeutics from $70.00 to $118.00 and gave the company an “outperform” rating in a research note on Monday, December 8th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $117.00.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.